Trials / Sponsors / Wugen, Inc.
Wugen, Inc.
Industry · 5 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukem T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 2 | 2025-01-31 |
| Active Not Recruiting | A Phase 1b Study of WU-NK-101 in Combination With Cetuximab Colorectal Cancer Metastatic, Squamous Cell Carcinoma of Head and Neck | Phase 1 | 2024-05-21 |
| Completed | A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Acute Myeloid Leukemia | Phase 1 | 2023-07-01 |
| Enrolling By Invitation | A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma | — | 2022-08-22 |
| Completed | A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refrac T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 1 | 2022-01-14 |